Interestingly, the immunosensor was applied to investigate Bcl-2 and Bax expressions from nilotinib-treated chronic myeloid leukemia K562 cells, and to evaluate the drug effect through the Bax/Bcl-2 ratio. The gene discussed is BAX; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.